For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Scientists have identified a promising target for treatment of a devastating autoimmune disease affecting the brain.

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Title: Gemini restores normal innate immune response in CKD patients Presenter: Robin Marsden, Senior Vice President of Biology, Revelation Biosciences Date/Time: Sunday, March 29, 2026 5:30 p.m.

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.

Kanazawa University, in collaboration with Osaka University and the National Institutes for Quantum Science and Technology, ...

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk’s Wegovy and ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Transient receptor potential canonical channels are essential for maintaining the function of human pulmonary endothelial cells in PAH.

FDA Breakthrough designation supports development of a point-of-care test for detecting folate receptor autoantibodies ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...